伐度司他(Vafseo)各版本的购买方式

Valadostat is an oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor in clinical practice and is used to improve anemia symptoms in patients with dialysis-dependent chronic kidney disease (CKD). This article will provide a detailed analysis of its purchase method, medication precautions, and medication guidance for special populations.

How to purchase various versions of Vafseo

Vadostat is currently not approved for marketing in mainland China, and patients cannot purchase it through local hospitals or pharmacies. Patients can obtain it in the following two ways. One is to purchase it with a prescription from a medical institution in a country that has been approved for marketing, and the other is to order online through a compliant cross-border medical platform. A doctor's prescription and other proofs are required.

When purchasing online, you need to choose a platform that supports drug traceability and verify the batch number, production date and expiry date on the drug packaging, which is usually 36 months. Low-price channels may carry the risk of counterfeit and substandard drugs, and patients need to carefully verify the platform's qualifications to avoid purchasing ineffective or harmful products.

Precautions for Valostat (Vafseo)

Scientific medication can reduce the chance of side effects. The following are specific precautions:

Drug combination contraindications and interval requirements

Avoid taking vadostat with iron-containing drugs at the same time, and the interval must be at least 1 hour. When vadostat is used in combination with simvastatin, the statin dose needs to be limited to 20 mg/day to prevent the risk of muscle damage. If a phosphate binder is required, it is recommended to take it 1 hour before or 2 hours after taking vadostat.

Liver function monitoring and dose adjustment

ALT, AST and bilirubin need to be detected before treatment, and liver function should be reviewed monthly in the initial stage of treatment. If ALT/AST is >3 times the normal value or accompanied by jaundice, the drug needs to be permanently discontinued and hepatoprotective treatment required. Mild abnormalities can maintain the dose, but the monitoring interval needs to be shortened to every 2 weeks. If the hemoglobin (Hb) rise rate exceeds 1g/dL/2 weeks, the medication needs to be suspended, and the dose will be reduced to 150mg/day after Hb drops to ≤11g/dL.

Evaluation of long-term efficacy

If Hb does not reach the target or frequent blood transfusions are still required after 24 weeks of treatment, the cause of anemia needs to be re-evaluated, other factors such as iron deficiency and chronic inflammation need to be ruled out, and the treatment plan should be adjusted if necessary.

What are the special medication groups for Valostat (Vafseo)?

Some patients need to pay special attention to the medication requirements. The following is specific guidance:

Pregnant and lactating women

Animal studies have shown that high-dose Vafseo components may affect fetal development. Pregnant women should only use it when it is clear that the benefits of treatment outweigh the risks. Breastfeeding women need to suspend breastfeeding until 2 days after the last dose to avoid drug transfer through breast milk.

Children and patients without dialysis

It is contraindicated in children under 18 years old and patients with chronic kidney disease who have not received dialysis. Use in patients without dialysis may increase the risk of death, stroke, etc., and the indications must be strictly followed.

Elderly patients and patients with liver disease

Patients over 65 years old do not need to adjust the dosage, but they need to strengthen cardiovascular and liver function monitoring. It is contraindicated in patients with cirrhosis or acute liver disease. Patients with Child-Pugh class B do not need to reduce the dose, but liver function indicators need to be reviewed monthly.

Patients with chronic kidney disease need to adhere to a low-salt, low-phosphorus diet and regularly monitor blood pressure, blood potassium and blood phosphorus to prevent cardiovascular complications.